37 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
resulting from injury, sickness or disease for a period of (A) six (6) consecutive months or (B) an aggregate of nine (9) months (whether
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
5 Dec 23
Departure of Directors or Certain Officers
7:15pm
resulting from injury, sickness or disease for a period of (A) six (6) consecutive months or (B) an aggregate of nine (9) months (whether
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
27 Nov 23
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
8:45am
limited or modified.
8. REMEDIES. Employee acknowledges that a violation of the terms of this Agreement may give rise to irreparable injury
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
or emotional incapacity resulting from injury, sickness or disease for a period of (A) six (6) consecutive months or (B) an aggregate of nine (9) months
8-K
EX-99.1
nyow7duj7t5ra60gtjn
27 Sep 23
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
8:45am
424B5
6ytyg 1t0
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-10.1
4af3un5exo bkeddxf
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
424B5
yr3nbyybq
7 Jun 21
Prospectus supplement for primary offering
4:21pm
424B5
sk3 t99d288
11 Mar 21
Prospectus supplement for primary offering
9:19am
424B4
crwq91 cl4
17 Feb 21
Prospectus supplement with pricing info
7:14am
8-K
EX-14.1
y9zyp5 5jvjmza6b7v6
6 Nov 20
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
9:18am
424B3
yy9ti8j4ybnc6dnq 4sd
2 Oct 20
Prospectus supplement
9:25am